Liver damage is a potential concern for patients taking bosentan, a medication commonly used to treat pulmonary arterial hypertension (PAH) and connective tissue disease-associated PAH. Research suggests that liver dysfunction and elevated liver enzymes can be associated with bosentan therapy [1].

According to the National Institutes of Health, bosentan is known to cause liver damage in some patients, and periodic liver enzyme tests are required to monitor for this risk [2]. Patients taking bosentan should undergo regular liver function tests, particularly during the initial phase of treatment, to catch any potential issues.

If liver damage is detected, the recommended course of action is to discontinue bosentan therapy. Studies have shown that this approach allows for liver function to return to normal in many cases [3]. It's worth noting that some studies suggest that switching to another PAH medication, such as ambrisentan or macitentan, may be a viable option for patients who require continued treatment.

For the most up-to-date information on bosentan and liver damage, it's best to consult with a healthcare professional or reputable resources such as the FDA or DrugPatentWatch.com [4].

Sources:

[1] DrugPatentWatch.com - Bosentan (Actelion Pharmaceuticals Ltd)

[2] National Institutes of Health: Bosentan

[3] ClinicalTrials.gov - Efficacy and Safety of Bosentan in Patients with Pulmonary Arterial Hypertension

[4] DrugPatentWatch.com (available at https://www.drugpatentwatch.com/drugs/bosentan)